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The gastrointestinal tract is continuously exposed to foreign
antigens—mainly derived from the commensal microbiota
and food antigens—but occasionally to those derived from
invading bacteria, viruses, and tumoral antigens. Therefore,
the immune systemof the gut has a unique capacity to balance
the mechanisms of tolerance in health and those creating a
proper defensive immune response in disease. Changes in
such delicate balance are usually linked to the development
of gastrointestinal pathology. Despite its central role in
human health and disease, most of the current knowledge of
mucosal immunology of the gastrointestinal tract is mainly
obtained from experimental murine models. Although the
mechanisms of intestinal immunity in mouse and human
have similar output, the specific pathways throughwhich they
are elicited are different [1, 2]. It is essential to fill in this gap in
our current knowledge of the human immune system of the
gastrointestinal tract in order to understand the pathogenesis
and be able to design rational therapies to manage acute and
chronic inflammatory gastrointestinal disease. In this special
issue, we aimed to gain depth into the current understanding
of immune processes in the human gastrointestinal tract in
health and disease by selecting work in progress of active
investigators in the field.
L. Pastorelli et al. review the role of a new cytokine IL-
33, member of the IL-1 family, in promoting host defense
against parasite and involved in the pathogenesis of ulcerative
colitis. The authors discuss some contradictory reports on
IL-33 function in the gastrointestinal mucosa, where it has
been reported either to enhance inflammatory responses or
to promote epithelial integrity [3, 4].
Significant advances have been achieved in the under-
standing of the pathogenesis of inflammatory bowel disease
(IBD), and new therapy targets are cytokines as well as their
receptors and signaling pathways [5]. In this issue, F. Scalda-
ferri et al. review the several immune factors taking part in
inflammatory bowel disease and how they are modulated in
the course of therapy aiming to identify potential targets to
control. These authors have confidence that new emerging
techniques, like microarray analysis or miRNA analysis,
which are able to assess immune signatures in response to
therapy, could help to identify good candidates for mucosal
prognostic biomarkers, together with new therapeutic targets
for future research.
Vascular endothelial growth factor (VEGF) is a pre-
dominant angiogenic factor, and recent studies using tissue
microarray blocks of VEGF-A, VEGF-C, VEGFR-2, and
VEGFR-3 expression have shown an association to progres-
sion, invasion, andmetastasis leading to poorer survival rates
and prognosis [6]. G. Karamanolis et al. show an increased
expression of both VEGF and CD31 in postradiation rectal
biopsy specimens, suggesting that the blockage of VEGFmay
represent a therapeutic option in patients with these severe
conditions that is refractory to available therapies.
Recent works suggest that in coeliac disease both the
innate and the acquired immune response are involved in the
inflammation initiated and maintained by gluten and key to
the development of autoimmunity in this common disease
[7]. A small fraction of patients become refractory to the
gluten-free diet, the only current available treatment [8, 9].
Recent studies suggest that it is more frequently observed
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in Europe than in the United States [10]. It is characterized
by persistent or recurrent symptoms of malabsorption and
intestinal villous atrophy. In this issue, S. Gross et al. have
studied refractory CD type II (RCDII), a particular subtype
with extreme bad prognosis and in fact it is considered a
low-grade intraepithelial lymphoma [11]. Gross et al. have
found that IL-13 may play a key role as a proinflammatory
cytokine since it is correlated with IL-17A production and
to other TH1 and TH2 cytokines, but not to the regulatory
cytokine IL-10, thus confirming their hypothesis that the
immune response is differentially regulated by cytokines in
active coeliac disease versus RCDII. This finding opens new
mechanisms to study further in order to understand the
pathogenesis of this condition.
Obesity, the modern epidemics, is according to a new
vision associated with chronic low-grade inflammation, and
the intestinal microflora may be responsible for inducing
these changes [12]. Since fecal microbiota transplantation re-
establishes a balanced intestinal flora with resultant cure of
recurrent clostridium difficile infection [13], other conditions
may benefit from this approach. In this issue, R. Mehta et al.
have studied gene expression profile in gastric tissue of
morbidly obese patients with different histological forms of
nonalcoholic fatty liver disease (NAFLD) and have identified
an altered profile for several inflammatory molecules. This
finding may be responsible for the pathogenesis of obesity-
related NAFLD. Previously, it had been demonstrated that
alterations in intestinalmicrobiota are associatedwith obesity
and six weeks after infusion of microbiota from lean donors
increased insulin sensitivity of recipients along with levels
of butyrate-producing intestinal microbiota. Thus suggesting
that intestinal microbiota might be developed as therapeutic
agents to increase insulin sensitivity in humans, however,
increased knowledge of the intestinal microbiota in health
maintenance as well as controlled trials of fecal microbiota
transplantation is needed before it can be accepted to be used
clinically [14, 15].
The activation of several cytosolic pathogen recognition
receptors allows the assembly of the inflammasome, a mul-
timeric complex platform that leads to the activation of the
innate immune system [16]. In their paper presented in this
issue, T. Nunes and H. S. de Souza review our current knowl-
edge on the inflammasome. The known molecular structure,
its importance in maintaining intestinal homeostasis, and its
critical mechanisms of the inflammasome are described in
the context of chronic inflammatory disorders in the human
gut such as inflammatory bowel diseases (IBD) and intestinal
cancer.
M. Witkowska and P. Smolewski, in this issue, review the
role of Helicobacter pylori infection in chronic inflammation
and the subsequent genomic transformation and develop-
ment. Knowledge on the etiology, pathogenesis, treatment,
and follow-up of gastric mucosa-associated lymphoid tissue
(MALT) lymphoma is providing more insight into mecha-
nisms of inflammation of this infection that is fortunately
continuously decreasing in the western world. Helicobacter
pylori eradication is a first-line treatment of gastric MALT
lymphoma; however, a significant percentage of patients do
not respond to treatment. Recently, it has been found that
a high number of Treg cells or a high ratio of Treg cells to
the total number of CD4+ T cells in gastricMALT lymphoma
could predict responsiveness to eradication therapy [17].
Manipulation of gut microbiota composition by using
probiotics is being explored as a promising avenue of prophy-
lactic and therapeutic intervention against gut inflammation.
Current evidence provides support for the consideration of
probiotics therapy for intestinal diseases, keeping in mind
that efficacy of probiotics is strain and disease specific. The
variety of studies carried outwith distinct strains of probiotics
bacteria has suggested heterogeneous and strain-specific
effects. Because of the limitations of most studies conducted
with probiotics, with regard to the power of the study, deficit
of human studies, randomization, use of different strains, and
lack of standardizedmethodology, it remains difficult to draw
firm conclusions from the current trials [18]. In this issue,
R. Sengupta et al. discuss the role of cell surface-associated
molecules in the probiotics and their host receptor. These
mechanisms will help to have a better understanding of the
probiotics-host crosstalk and contribute to improve therapies
to treat or prevent gastrointestinal inflammation in IBD.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the
most highly prescribed drugs in the world for the treatment
of pain, inflammation, and fever. However, these drugs
produce serious gastrointestinal complications during long-
term administration, particularly in the elderly [19]. M. Sinsa
et al., in this issue, describe the action of NSAIDs as a
cause of morbidity/mortality related to gastric and duodenal
ulcer disease and discuss different approaches to prevent or
minimize such adverse effects. However, they caution that
these treatments are effective to some extent, but most of
them are also associated with other risks, and there is a
need to develop novel therapeutic agents to make the use of
NSAIDs safer.
Particular probiotics of the Lactobacillus species appear
to stimulate health promoting effects in the gastrointesti-
nal tract, such as pathogen inhibition by competing with
invading bacteria, immunomodulation, and enhancement
of the epithelial integrity [20] not only via direct contact
but also through bacteria derived metabolites [21]. Recent
works suggest that dendritic cells (DC) control the nature and
location of immune response that seems to play a central role
in ulcerative colitis [22]. Dendritic cells may orchestrate the
abnormal response against the commensal microbiota that
is present in these patients [23]. E. R. Mann et al. describe
an abnormal phenotype and function of circulating DC in
patients suffering from ulcerative colitis which are partially
restored by the probiotic strain Lactobacillus casei Shirota.
It has been a pleasure to select the work presented in these
areas by experts in the respective fields. We hope that their
findings will help to enrich the knowledge of the mediators
of inflammation of the human gastrointestinal tract and
will form the basis for new approaches to the treatment of
common infections and those conditions that although rare




Mediators of Inflammation 3
References
[1] D. L. Gibbons and J. Spencer, “Mouse and human intestinal
immunity: same ballpark, different players; different rules, same
score,”Mucosal Immunology, vol. 4, no. 2, pp. 148–157, 2011.
[2] E. R. Mann, J. D. Landy, D. Bernardo et al., “Intestinal dendritic
cells: their role in intestinal inflammation, manipulation by
the gut microbiota and differences between mice and men,”
Immunology Letters, vol. 150, pp. 30–40, 2013.
[3] L. Pastorelli, C. De Salvo, M. A. Cominelli, M. Vecchi, and T.
T. Pizarro, “Novel cytokine signaling pathways in inflammatory
bowel disease: insight into the dichotomous functions of IL-33
during chronic intestinal inflammation,” Therapeutic Advances
in Gastroenterology, vol. 4, no. 5, pp. 311–323, 2011.
[4] J. B. Seidelin, G. Rogler, and O. H. Nielsen, “A role for
interleukin-33 in TH2-polarized intestinal inflammation,”
Mucosal Immunology, vol. 4, no. 5, pp. 496–502, 2011.
[5] M. Scharl, S. R. Vavricka, and G. Rogler, “Review: new anti-
cytokines for IBD: what is in the pipeline?” Current Drug
Targets. In press.
[6] S. F. Martins, E. A. Garcia, M. A. Luz, F. Pardal, M. Rodrigues,
andA. L. Filho, “Clinicopathological correlation and prognostic
significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3
expression in colorectal cancer,” Cancer Genomics Proteomics,
vol. 10, pp. 55–67, 2013.
[7] B. Jabri and L. M. Sollid, “Tissue-mediated control of immuno-
pathology in coeliac disease,” Nature Reviews Immunology, vol.
9, no. 12, pp. 858–870, 2009.
[8] M. Hadithi and A. S. Pen˜a, “Current methods to diagnose
the unresponsive and complicated forms of coeliac disease,”
European Journal of Internal Medicine, vol. 21, no. 4, pp. 247–
253, 2010.
[9] J. F. Ludvigsson, D. A. Leffler, J. C. Bai et al., “The Oslo defi-
nitions for coeliac disease and related terms,” Gut, vol. 62, pp.
43–52, 2013.
[10] G. Malamut and C. Cellier, “Is refractory celiac disease more
severe in old Europe,”American Journal of Gastroenterology, vol.
106, no. 5, pp. 929–932, 2011.
[11] G. Malamut, J. A. Murray, and C. Cellier, “Refractory celiac
disease,” Gastrointestinal Endoscopy Clinics of North America,
vol. 22, pp. 759–772, 2012.
[12] M. Hvistendahl, “Pigs as stand-ins for microbiome studies,”
Science, vol. 336, no. 6086, p. 1250, 2012.
[13] E. Mattila, R. Uusitalo-Seppa¨la¨, M. Wuorela et al., “Fecal trans-
plantation, through colonoscopy, is effective therapy for recur-
rent Clostridium difficile infection,” Gastroenterology, vol. 142,
no. 3, pp. 490–496, 2012.
[14] O. C. Aroniadis and L. J. Brandt, “Fecal microbiota transplan-
tation: past, present and future,” Current Opinion in Gastroen-
terology, vol. 29, pp. 79–84, 2013.
[15] A.Vrieze, E.VanNood, F.Holleman et al., “Transfer of intestinal
microbiota from lean donors increases insulin sensitivity in
individuals with metabolic syndrome,” Gastroenterology, vol.
143, pp. 913–916, 2012.
[16] R. M. Nanau and M. G. Neuman, “Metabolome and inflamma-
some in inflammatory bowel disease,” Translational Research,
vol. 160, pp. 1–28, 2012.
[17] Y. Iwaya, M. Kobayashi, M. Momose et al., “High levels of
FOXP3 regulatory T cells in gastric MALT lymphoma predict
responsiveness to helicobacter pylori eradication,”Helicobacter,
2013.
[18] O. P. Karimi and A. S. Pen˜a, “Probiotics in clinical practice
as therapeutics against enteric disorders,” in Probiotic Bacteria
and Enteric Infections. Cytoprotection by probiotics, J. J. Malago,
J. F. J. G. Koninkx, and R. Marinsek-Logar, Eds., pp. 355–373,
Springer, New York, NY, USA, 2011.
[19] W. E. Smalley, W. A. Ray, J. R. Daugherty, and M. R. Griffin,
“Nonsteroidal anti-inflammatory drugs and the incidence of
hospitalizations for peptic ulcer disease in elderly persons,”
American Journal of Epidemiology, vol. 141, no. 6, pp. 539–545,
1995.
[20] S. C. Ng, A. L. Hart, M. A. Kamm, A. J. Stagg, and S. C. Knight,
“Mechanisms of action of probiotics: recent advances,” Inflam-
matory Bowel Diseases, vol. 15, no. 2, pp. 300–310, 2009.
[21] D. Bernardo, B. Sanchez, H. O. Al-Hassi et al., “Microbiota/host
crosstalk biomarkers: regulatory response of human intestinal
dendritic cells exposed to Lactobacillus extracellular encrypted
peptide,” PLoS One, vol. 7, Article ID e36262, 2012.
[22] A. L. Hart, H. O. Al-Hassi, R. J. Rigby et al., “Characteristics
of intestinal dendritic cells in inflammatory bowel diseases,”
Gastroenterology, vol. 129, no. 1, pp. 50–65, 2005.
[23] J. Qin, R. Li, J. Raes et al. et al., “A human gut microbial gene
catalogue established bymetagenomic sequencing,”Nature, vol.
464, pp. 59–65, 2010.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
